Get to know our clinical trials
Ensayo de elacestrant en combinación con abemaciclib en mujeres y varones con metástasis cerebrales causadas por un cáncer de mama con receptores de estrógenos y sin obreexpresión del receptor HER2 (ELECTRA).
THIS STUDY IS BEING CONDUCTED TO DETERMINE WHETHER ELACESTRANT IS SAFE AND TOLERABLE WHEN GIVEN WITH OR WITHOUT ANOTHER DRUG CALLED ¿ABEMACICLIB¿. IN PHASE 2, THE RESEARCHERS WILL ALSO INVESTIGATE WHAT EFFECT ELACESTRANT (WHEN GIVEN WITH OR WITHOUT ABEMACICLIB) HAS ON THEIR BRAIN TUMORS
Technical Summary
- ESTUDIO DE FASE 1B-2, SIN ENMASCARAMIENTO, MULTICÉNTRICO, EN EL QUE SE EVALÚA ELACESTRANT EN COMBINACIÓN CON ABEMACICLIB EN MUJERES Y VARONES CON METÁSTASIS CEREBRALES CAUSADAS POR UN CÁNCER DE MAMA CON RECEPTORES DE ESTRÓGENOS Y SIN OBREEXPRESIÓN DEL RECEPTOR HER2 (ELECTRA).
- Code EudraCT: 2022-001087-10
- Protocol number: ELA-0121
- Promoter: Stemline Therapeutics
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.